Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling Pathway

Sepsis is a leading cause of death in patients with severe infection worldwide. Remifentanil is an ultra-short-acting, potent opioid analgesic. In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian-ning, Ma, Yang, Wei, Xi-yan, Liu, Ke-yin, Wang, Hao, Han, Hui, Cui, Yi, Zhang, Ming-xiang, Qin, Wei-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012251/
https://www.ncbi.nlm.nih.gov/pubmed/32082073
http://dx.doi.org/10.1155/2019/3013716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012251/
https://www.ncbi.nlm.nih.gov/pubmed/32082073
http://dx.doi.org/10.1155/2019/3013716

Ejemplares similares